Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada
Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )
16 Sep 2024

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy

Prof Pascale Tomasini - Aix-Marseille University, Marseille, France
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy ( Prof Pascale Tomasini - Aix-Marseille University, Marseille, France )
16 Sep 2024

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden
ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )
16 Sep 2024

No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBC

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA
No OS improvement over chemo from capivasertib plus paclitaxel in advanced TNBC ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )
16 Sep 2024

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours

Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )
16 Sep 2024

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip
ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )
16 Sep 2024

Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal

Dr Sheela Rao - The Royal Marsden, London, UK
Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal ( Dr Sheela Rao - The Royal Marsden, London, UK )
15 Sep 2024

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard
Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )
15 Sep 2024

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer

Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain
TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer ( Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain )
15 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024